Grifols is committed to quality
Grifols owns one of the largest plasma collection networks in the world, and is committed to ensuring that its products meet excellent quality standards and are available to the patients who need them.
One of the largest plasma collection networks in the world, with a production capacity you can rely on1
![Doctor and Patient with questionnaire](/documents/4265257/4265676/doctor-patient-questionnaire-small.png/4213f990-c23d-4310-868f-58d2c0cfa688?t=1516033553615)
Selected donors
All donors thoroughly screened and tested
![grey box](/documents/4265257/4265676/grey-box-small.png/12d5fdf7-d5f4-4c34-9c3b-68f91dd012d7?t=1516033553982)
Identification and verification by barcodes
Full traceability from each donation to final product
![Immunoassay (ELISA) testing for each donation](/documents/4265257/4265676/immunoassay-ELISA-small.png/dfe0d824-b907-4b88-8b66-6b5d5719387c?t=1516033554226)
Immunoassay (ELISA) testing for each donation
Each unit is tested by ELISA for HBsAg, HIVAb, and HCVAb
![Minipool Nucleic Acid Testing (NAT)](/documents/4265257/4265676/minipool-nucleic-acid-testing-small.png/3464c75c-6717-4191-baf6-d6ff698de9f4?t=1516033554630)
Minipool nucleic acid testing (NAT)
NAT testing in minipools of ≤512 units for HIV, HBV, HCV, HAV, and virus B19
![Inventory-hold and look-back](/documents/4265257/4265676/inventory-hold-look-back-small.png/bfa935a7-7548-4271-af0d-e3cbdc0b2626?t=1516033554361)
Inventory hold
Every unit of plasma is held in inventory for 60 days before being released into production
![Final computer verification](/documents/4265257/4265676/final-computer-verification-small.png/0246e9bc-080f-4f92-b4a0-bc98eb06663c?t=1516033553806)
Final computer verification
The only way plasma is released
ELISA, enzyme-linked immunosorbent assay; HAV, hepatitis A virus; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; HCVAb, hepatitis C virus antibody; HIV, human immunodeficiency virus; HIVAb, human immunodeficiency virus antibody.
Flebogamma® DIF is registered in more than 40 countries
Grifols is committed to assuring continued access of IVIG to the people around the world who depend on this life enhancing medicine
![Countries where Flebogamma DIF is registered](/documents/4265257/4265676/grifols-locations-image.png/6f58bec9-c317-410d-ae0e-0a75f124a5d4?t=1516033554119)
All IVIGs are not the same; the process makes the product2
![Each IVIG manufacturer has its own unique process](/documents/4265257/4265676/ivig-manufacturer-has-own-process.png/6c996206-70dc-445b-aec9-fdfc930d26e0?t=1533811379986)
Each IVIG manufacturer has its own unique:
- Production process
- Pathogen elimination methods
- Final formulation and composition
This makes each product different
For this reason, clinical outcomes, including both safety and efficacy, might also differ among brands2
Dual inactivation (pasteurization and solvent/detergent treatment) and nanofiltration (20 nm) provide peace of mind for you and your patients3-5
The Flebogamma® DIF production process includes 3 validated specific pathogen-elimination steps, providing a broad safety margin4,5
![Steps in pathogen elimination](/documents/4265257/4265676/steps-pathogen-elimination.png/1007a210-f69c-4b60-98b7-f0d70b3642e8?t=1521796275330)
In addition to these 3 validated specific steps, the process involves 4 validated non-specific pathogen reduction steps (fraction I precipitation, incubation during fraction II and III precipitation, PEG precipitation, and acid pH treatment)4,5
References:
- Data on File. Instituto Grifols, S.A.
- Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):592-599.
- Siegel J. Immune globulins: therapeutic, pharmaceutical, cost, and administration considerations. Pharmacy Practice News. Special Edition, Educational Reviews. January 2014.
- Belda FJ, Caballero S, Díez JM, et al. Study of Planova™ 20N nanofiltration as applied to Flebogamma DIF. In: Etzioni A, Gambineri E, editors. Proceedings of the 15th Meeting of the European Society of Immunodeficiencies; October 3-6, 2012, Florence, Italy.
- Jorquera JI. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy. Clin Exp Immunol. 2009;157(suppl 1):17- 21.
- Jose M, Marzo N, Bono M, et al. Pasteurization inactivates clotting enzymes during Flebogamma and Flebogamma DIF production. WebmedCentral Immunotherapy. 2011;2(5):WMC001917. doi: 10.975/journal.wmc.2011.001917.